Actively Recruiting

FEMALE
NCT04660435

To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer

Led by Fondazione Sandro Pitigliani · Updated on 2025-02-26

150

Participants Needed

1

Research Sites

326 weeks

Total Duration

On this page

Sponsors

F

Fondazione Sandro Pitigliani

Lead Sponsor

C

Clinical Research Technology S.r.l.

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a multi-center biomarkers study aiming to prospectively collect biological samples from patients with ER+ and HER2-negative metastatic breast cancer, who are candidate to first-line treatment with an aromatase inhibitor and a CDK4/6 inhibitor as per standard clinical practice. Blood and tissue samples will be collected for biomarker analysis, including thymidine kinase1 activity, gene expression signatures and circulating tumor DNA.

CONDITIONS

Official Title

To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer

Who Can Participate

FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Women aged 18 years or older with metastatic breast cancer
  • Estrogen receptor-positive and HER2-negative disease confirmed on primary tumor or metastatic biopsy
  • No prior systemic therapy for metastatic breast cancer (prior hormonal or chemotherapy in neo/adjuvant setting allowed)
  • Candidate for first-line treatment with an aromatase inhibitor and a CDK4/6 inhibitor per local practice
  • Evaluable disease according to RECIST 1.1 (measurable or non-measurable disease)
  • Provide a formalin-fixed, paraffin-embedded tumor block from a metastatic biopsy before study entry (bone-only disease patients may join without metastatic biopsy)
  • Agree to provide blood samples at specified study time points
Not Eligible

You will not qualify if you...

  • Metastatic disease limited only to the central nervous system without other metastatic sites, unless CNS metastasis has been surgically removed and tumor tissue is available
  • History of non-breast cancers within the last 5 years except for in situ cervical carcinoma or treated basal or squamous cell skin cancer

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Hospital Santo Stefano

Prato, Tuscany, Italy, 59100

Actively Recruiting

Loading map...

Research Team

L

Luca Malorni

CONTACT

C

Chiara Biagioni

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here